Eisai, Biogen To Discontinue Elenbecestat Phase III Studies - Quick Facts

(RTTNews) - Eisai Co. Ltd., a global research and development-based pharmaceutical company headquartered in Japan, and Biogen Inc. (BIIB) have decided to discontinue the Phase III clinical studies of BACE inhibitor elenbecestat in patients with early Alzheimer's disease. The Data Safety Monitoring Board recommended to discontinue these trials due to unfavorable risk-benefit ratio.

The Phase III program for elenbecestat consisted of two global clinical studies with identical protocols. Both studies were placebo-controlled parallel-group Phase III studies designed to assess the efficacy of elenbecestat for treatment in about 2,100 patients.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More